Pudendal Atherosclerosis by IVUS-NIRS in Men With Coronary Artery Disease (PUDENDAL-NIRS)
Characterization of Internal Pudendal Atherosclerosis by Intravascular Ultrasound and Near-Infrared Spectroscopy and Its Relationship With Erectile Dysfunction in Men With Coronary Artery Disease
This prospective, single-center, exploratory study will evaluate the association between atherosclerotic and lipid plaque burden in the internal pudendal arteries, assessed by intravascular ultrasound and near-infrared spectroscopy (IVUS-NIRS), and the severity of erectile dysfunction in adult men with documented or suspected coronary artery disease undergoing clinically indicated coronary angiography.
After completion of the clinically indicated coronary procedure, eligible and hemodynamically stable participants with favorable pelvic vascular anatomy will undergo selective pudendal angiography and investigational IVUS-NIRS imaging of one or both internal pudendal arteries. Erectile function will subsequently be assessed within 30 days using the 5-item International Index of Erectile Function (IIEF-5).
The primary outcome will be the correlation between pudendal maxLCBI4mm and IIEF-5 score. Secondary analyses will characterize pudendal and coronary plaque burden, assess the relationship between pudendal and coronary lipid burden, evaluate associations with cardiovascular risk factors, and describe the technical feasibility and safety of pudendal IVUS-NIRS imaging.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: José Raúl Méndez Colin, MD
- Telefonní číslo: +52 55 2516 3465
- E-mail: dr.mendezcolin1989@gmail.com
Studijní záloha kontaktů
- Jméno: Luis Enrique Berumen Domínguez, MD
- Telefonní číslo: 5028 +52 55 2122 1100
- E-mail: luisberumen@hotmail.com
Studijní místa
-
-
Mexico City
-
Mexico City, Mexico City, Mexiko, 11200
- Nábor
- Hospital Central Militar
-
Kontakt:
- José Raúl Méndez Colin, MD
- Telefonní číslo: +52 55 2516 3465
- E-mail: dr.mendezcolin1989@gmail.com
-
Kontakt:
- Luis Enrique Berumen Domínguez, MD
- E-mail: luisberumen@hotmail.com
-
Vrchní vyšetřovatel:
- José Raúl Méndez Colin, MD
-
Dílčí vyšetřovatel:
- Luis Enrique Berumen Domínguez, MD
-
Dílčí vyšetřovatel:
- José Gadú Campos Salcedo, MD
-
Dílčí vyšetřovatel:
- Edwin García Sánchez, MD
-
Dílčí vyšetřovatel:
- Luis David Sánchez Mayo, MD
-
Dílčí vyšetřovatel:
- Aldo Figueroa Peña, MD
-
Dílčí vyšetřovatel:
- María Ximena Romo Cordero, MD
-
Dílčí vyšetřovatel:
- Roberto Paniagua Jiménez, MD
-
Dílčí vyšetřovatel:
- Eduardo Sánchez Cortés, MD
-
Dílčí vyšetřovatel:
- Ángel Leovigildo Alberto Delgado, MD
-
Dílčí vyšetřovatel:
- Alfredo Andrei Tort Hidalgo, MD
-
Dílčí vyšetřovatel:
- Cesar Gerardo Galván Vargas, MD
-
Dílčí vyšetřovatel:
- Mario Humberto Lozano Quintas, MD
-
Dílčí vyšetřovatel:
- Jorge Alberto Silva Rendón, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male participants aged 18 years or older.
- Documented or suspected coronary artery disease with a clinical indication for coronary angiography.
- Coronary IVUS-NIRS evaluation indicated by the treating interventional cardiologist.
- Sufficient clinical and hemodynamic stability to undergo the additional pudendal evaluation.
- Favorable pelvic vascular anatomy for selective angiography and safe advancement of the IVUS-NIRS catheter.
- Ability to complete the IIEF-5 questionnaire and provide information regarding sexual function.
- Written informed consent specifically for study participation and invasive evaluation of the internal pudendal arteries.
- Agreement to clinical follow-up by Cardiology and Urology.
Exclusion Criteria:
- Cardiogenic shock, hemodynamic instability, or acute clinical deterioration.
- Urgent or complicated coronary procedure in which prolonging the procedure would increase risk.
- Advanced kidney disease or high risk of kidney injury associated with additional contrast administration.
- Unfavorable iliofemoral or pelvic vascular anatomy for safe evaluation of the internal pudendal arteries.
- Severe coagulopathy, active bleeding, or contraindication to the invasive procedure.
- History of radical pelvic surgery or pelvic radiotherapy.
- Advanced prostate cancer or previous urologic treatment that predominantly explains erectile dysfunction.
- Severe untreated hypogonadism, advanced neurologic disease, or another predominant nonvascular cause of erectile dysfunction.
- Inability to reliably complete the IIEF-5 questionnaire.
- Refusal to participate or to provide study-specific written informed consent.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Pudendal IVUS-NIRS Evaluation
Participants will undergo selective angiography of the internal iliac and internal pudendal arteries followed, when technically feasible and clinically safe, by investigational IVUS-NIRS imaging of one or both internal pudendal arteries. |
Selective angiography of the internal iliac and internal pudendal arteries will be performed after completion of the clinically indicated coronary procedure to assess pelvic vascular anatomy and technical feasibility for intravascular imaging. When vascular anatomy and clinical conditions are considered suitable, an IVUS-NIRS catheter will be advanced into one or both internal pudendal arteries. Automated pullback imaging will be performed to assess vessel anatomy, plaque burden, lipid core burden index (LCBI), and maxLCBI4mm. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Correlation Between Pudendal maxLCBI4mm and IIEF-5 Score
Časové okno: At the pudendal IVUS-NIRS procedure and within 30 days after enrollment for IIEF-5 assessment
|
The association between the maximum lipid core burden index within a 4-mm segment (maxLCBI4mm) of the internal pudendal arteries, measured by IVUS-NIRS, and erectile function assessed by the 5-item International Index of Erectile Function (IIEF-5) will be evaluated using Spearman correlation. Pudendal maxLCBI4mm ranges from 0 to 1000, with higher values indicating greater lipid burden. IIEF-5 scores range from 5 to 25, with lower scores indicating more severe erectile dysfunction. |
At the pudendal IVUS-NIRS procedure and within 30 days after enrollment for IIEF-5 assessment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pudendal Artery Plaque Burden by IVUS
Časové okno: During the pudendal IVUS-NIRS procedure
|
Pudendal artery plaque burden will be quantified by intravascular ultrasound (IVUS) as the proportion of the vessel area occupied by plaque plus media. Measurements will include plaque burden, minimum lumen area, and angiographic percent stenosis in the evaluated internal pudendal arteries. |
During the pudendal IVUS-NIRS procedure
|
|
Pudendal Artery Lipid Burden by NIRS
Časové okno: During the index pudendal IVUS-NIRS procedure
|
Lipid burden in the internal pudendal arteries will be characterized using near-infrared spectroscopy (NIRS), including the Lipid Core Burden Index (LCBI) and maximum LCBI within any continuous 4-mm segment (maxLCBI4mm). If both internal pudendal arteries are evaluated, measurements from each side will be recorded and the highest maxLCBI4mm per participant will be used for the main analyses. |
During the index pudendal IVUS-NIRS procedure
|
|
Correlation Between Pudendal and Coronary maxLCBI4mm
Časové okno: During the index coronary and pudendal IVUS-NIRS procedures
|
The association between pudendal and coronary lipid burden will be assessed by correlating the highest pudendal maxLCBI4mm with the highest coronary maxLCBI4mm obtained by IVUS-NIRS. The correlation will be evaluated using Spearman correlation. |
During the index coronary and pudendal IVUS-NIRS procedures
|
|
Pudendal Atherosclerotic and Lipid Burden According to Erectile Dysfunction Severity
Časové okno: Within 30 days after enrollment
|
Pudendal atherosclerotic and lipid burden, including plaque burden and maxLCBI4mm, will be compared across erectile dysfunction severity categories defined by the IIEF-5 score: no erectile dysfunction, mild, mild-to-moderate, moderate, and severe erectile dysfunction. |
Within 30 days after enrollment
|
|
Spearman Correlation Between Pudendal maxLCBI4mm and LDL Cholesterol
Časové okno: At baseline
|
Spearman's rank correlation coefficient (rho) will be calculated between pudendal maxLCBI4mm measured by near-infrared spectroscopy (NIRS) and serum low-density lipoprotein cholesterol (LDL-C). Pudendal maxLCBI4mm is expressed as an index from 0 to 1000, with higher values indicating greater lipid burden. LDL-C is expressed in mg/dL. |
At baseline
|
|
Number of Participants With Successful Pudendal IVUS-NIRS Image Acquisition
Časové okno: Periprocedural
|
The number of participants in whom analyzable IVUS-NIRS images are successfully obtained from at least one internal pudendal artery will be reported. Successful image acquisition is defined as acquisition of images of sufficient quality for quantitative IVUS and NIRS analysis. |
Periprocedural
|
|
Procedure-Related Adverse Events
Časové okno: From the pudendal procedure through the 30-day study evaluation
|
Adverse events related to selective pudendal angiography and IVUS-NIRS imaging will be recorded, including arterial dissection, perforation, persistent vasospasm, thrombosis, bleeding, contrast-associated kidney injury, embolization, or other complications considered attributable to the investigational pudendal procedure. |
From the pudendal procedure through the 30-day study evaluation
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: José Raúl Méndez Colin, MD, Hospital Central Militar
- Ředitel studie: Luis Enrique Berumen Domínguez, MD, Hospital Central Militar
Publikace a užitečné odkazy
Obecné publikace
- Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, Salonia A, Deho F, Rigatti P, Montorsi F, Fiorentini C. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006 Nov;27(22):2632-9. doi: 10.1093/eurheartj/ehl142. Epub 2006 Jul 19.
- Erlinge D, Maehara A, Ben-Yehuda O, Botker HE, Maeng M, Kjoller-Hansen L, Engstrom T, Matsumura M, Crowley A, Dressler O, Mintz GS, Frobert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen L, Nordrehaug JE, Bleie O, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW; PROSPECT II Investigators. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021 Mar 13;397(10278):985-995. doi: 10.1016/S0140-6736(21)00249-X.
- Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319-26. doi: 10.1038/sj.ijir.3900472.
- Waksman R, Di Mario C, Torguson R, Ali ZA, Singh V, Skinner WH, Artis AK, Cate TT, Powers E, Kim C, Regar E, Wong SC, Lewis S, Wykrzykowska J, Dube S, Kazziha S, van der Ent M, Shah P, Craig PE, Zou Q, Kolm P, Brewer HB, Garcia-Garcia HM; LRP Investigators. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet. 2019 Nov 2;394(10209):1629-1637. doi: 10.1016/S0140-6736(19)31794-5. Epub 2019 Sep 27.
- Zacharias SK, Safian RD, Madder RD, Hanson ID, Pica MC, Smith JL, Goldstein JA, Abbas AE. Invasive evaluation of plaque morphology of symptomatic superficial femoral artery stenoses using combined near-infrared spectroscopy and intravascular ultrasound. Vasc Med. 2016 Aug;21(4):337-44. doi: 10.1177/1358863X16631420. Epub 2016 Mar 8.
- Rogers JH, Karimi H, Kao J, Link D, Javidan J, Yamasaki DS, Dolan M, Laird JR, Low RI. Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. Catheter Cardiovasc Interv. 2010 Nov 15;76(6):882-7. doi: 10.1002/ccd.22646. Epub 2010 Oct 6.
- Park HW, Her SH, Park BH, Han DS, Yuk SM, Kim DW, Youn CS, Jang H. Correlation between internal pudendal artery stenosis and erectile dysfunction in patients with suspected coronary artery disease. PLoS One. 2019 Nov 12;14(11):e0225179. doi: 10.1371/journal.pone.0225179. eCollection 2019.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Cévní onemocnění
- Kardiovaskulární choroby
- Duševní poruchy
- Onemocnění pohlavních orgánů, muž
- Mužská urogenitální onemocnění
- Srdeční choroba
- Arterioskleróza
- Arteriální okluzivní onemocnění
- Koronární onemocnění
- Ischémie myokardu
- Sexuální dysfunkce, fyziologické
- Sexuální dysfunkce, psychologické
- Ischemická choroba srdeční
- Erektilní dysfunkce
- Ateroskleróza
Další identifikační čísla studie
- HCM-PUDENDAL-NIRS-2026
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data (IPD) will not be shared because the study protocol and informed consent do not include a plan for external sharing of participant-level data. Study data will remain under institutional custody and will be used for the approved research objectives, analyses, and scientific publications while maintaining participant confidentiality.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .